Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07216313 · ClinicalTrials.gov registry record · Phase 1

A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants

A Phase 1 study, sponsored by Sagimet Biosciences.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target

NCT07216313: Completed Phase 1 study, sponsored by Sagimet Biosciences.

NCT07216313 is a Phase 1 study that has completed, run by Sagimet Biosciences. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07216313, a Phase 1 study, has completed, sponsored by Sagimet Biosciences.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

This is an open-label, 2-cohort study to evaluate the mutual DDI potential between denifanstat and resmetirom in healthy adult participants.

Interventions

  • DRUG Resmetirom
  • DRUG Denifanstat

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-09-30
Est. Completion 2025-10-20
Phase Phase 1
Sagimet Biosciences

7 total trials

What the finished NCT07216313 record still lists

NCT07216313 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).

The record links to 0 conditions, and to 2 interventions - of which Resmetirom is the first listed.

NCT07216313 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07216313 about?

NCT07216313 is a clinical study titled "A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants". This is an open-label, 2-cohort study to evaluate the mutual DDI potential between denifanstat and resmetirom in healthy adult participants.

What is the current status of trial NCT07216313?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-09-30. Estimated completion is 2025-10-20.

What interventions are being tested in trial NCT07216313?

The interventions under investigation include: Resmetirom (DRUG), Denifanstat (DRUG).

Who is sponsoring clinical trial NCT07216313?

This trial is sponsored by Sagimet Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07216313's enrollment target sits among peer trials

40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07216313, the US trial registry maintained by the National Library of Medicine. NCT07216313 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.